Embecta Corp. is a prominent global medical technology enterprise that operates as an independent, publicly traded corporation following its spin-off from Becton, Dickinson and Company. Inheriting a century-old legacy in diabetes care innovation, the company specializes in developing, manufacturing, and distributing injection devices, pen needles, and chronic care accessories designed to improve the daily lives of millions of insulin-dependent patients worldwide.